Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12478364 | 0.84 | CES2 (0.60) | DAOCES2CES1ALDH1A1PKM | |
| SCHEMBL6826976 | 0.81 | DAO (0.57) | DAOALDH1A1L3MBTL1MAPTGAA | |
| SCHEMBL5859674 | 0.80 | DAO (0.71) | DAOCES2CES1MAPTNPSR1 | |
| SCHEMBL5099644 | 0.76 | DAO (0.50) | DAOALDH1A1PKMHTTMAPT | |
| SCHEMBL3752532 | 0.73 | DAO (0.61) | DAOCES2CES1HTTMAPT | |
| SCHEMBL7368425 | 0.72 | DAO (0.71) | DAOCES2CES1ALDH1A1MAPT | |
| SCHEMBL6025725 | 0.72 | DAO (0.39) | DAOHTTMAPTGAASMN1; SMN2 | |
| SCHEMBL1128796 | 0.71 | CES2 (0.59) | DAOCES2CES1ALDH1A1MAPT | |
| SCHEMBL7656479 | 0.71 | DAO (0.63) | DAOCES2CES1MAPTNPSR1 | |
| SCHEMBL15979699 | 0.71 | DAO (0.63) | DAOCES2CES1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119626-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | SUGAWARA KAZUTOSHI | 2009-11-26 | — | — | US | disclosed |
| US-7514439-B2 | Oxime derivative and preparations thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1907387-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007007886-A1 | AN OXIME DERIVATIVE AND PREPARATIONS THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132479-A1 | Oxime Derivative and Preparations Thereof | GCK, KHK, GCKR | DAO 162/4885CES2 933/4885CES1 1071/4885 |
| US-20090291936-A1 | OXIME DERIVATIVE AND PREPARATIONS THEREOF | GCK, KHK, GCKR | DAO 162/4885CES2 933/4885CES1 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.